Sellbyville, DE -- (SBWIRE) -- 01/10/2019 -- Cell Line Development Market to exceed USD 7 billion by 2023 as per a new research report.
Growing demand for monoclonal antibodies (MAbs), cell and gene therapy, should drive cell line development market over the forecast timeframe. Technological advancement coupled with increasing need for cancer therapeutics fuel the industry growth.
Increasing incidence rate of auto immune disorder that requires effective and initial treatment are some determinants that will propel cell line development market growth opportunities. In addition, expansion of the healthcare infrastructure associated with favorable government initiatives and development of novel technologies is projected to stimulate cell line development market.
Constant R&D for steady & reliable cell lines as well as the introduction of technologically advanced procedures such as, micro bioreactor for large scale bioproduction and single use bioreactor are the factors that deliver industry with profitable future growth opportunities. Moreover, increasing demand for novel vaccines, drugs, therapeutic proteins, and biosimilars are expected to upsurge business growth over the forecast timeframe. Development of constant and authenticated cell lines may restrain cell line development market growth.
Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/429
Increasing demand for cell line development equipment due to growing usage of advanced technologies aided to grow cell lines and increased vaccine production.
The non-mammalian cell line development accounted for lucrative growth. The growth is attributed due to the technology used such as, somatic embryogenesis for the non-mammalian cell culture and continuous R&D for manufacturing composite proteins such as hormone erythropoietin in complex plants or insect cells as it is possible to cultivate these cultures on large-scale.
Recombinant cell lines should propel industry growth due to its wide application in manufacturing of biologics and other cell lines. Growing demand for drug screening and toxicity testing should further drive industry growth. Primary cell lines are expected to witness significant progress due to increasing adoption associated with stem cell culture and regenerative medicine.
Implementation of cell lines for cell toxicity testing is expected to upsurge industry over the forecast period owing to increased technological development and high chemical compounds industrialized for high throughput screening.
U.S. cell line development market led the North America owing to increased government initiatives in product expansion, existence of sophisticated healthcare infrastructure and growing awareness about monoclonal antibodies for the treatment of cancer.
Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/429
Emerging economies such as, India and China witness profitable cell line development market growth due to increasing trend in research outsourcing, existence of high untouched prospects involved with growing patient awareness concerning effective measures for cancer and therapeutics.
Companies operating in cell line development includes Lonza Group, WuXi AppTec, American Type Culture Collection (ATCC), Corning, Sigma-Aldrich Corporation, Selexis, Sartorious, GE Healthcare, European Collection of Cell Cultures (ECACC) and Thermo Fisher Scientific. Companies are merging their market position by focusing on research and development activities to progress innovative and novel cost-effective technologies.